Mandate

Vinge has advised KCG in connection with the acquisition of Neonet

September 16, 2016

Vinge has advised KCG Holdings, Inc. on its acquisition of Neonet Securities AB from inter alios Hay Tor Capital LLP, KAS Bank N.V., Nordic Capital / Cidron Delphi Intressenter AB and Neonet management. Neonet is a Swedish independent capital markets services provider offering a comprehensive suite of advanced algorithmic trading, smart order routing and sales.

KCG is a leading independent securities firm offering investors a range of services designed to address trading needs across asset classes, product types and time zones. The acquisition is a strategic supplement to KCG’s business concept and will strengthen KCG’s reach in continental Europe and will enable both KCG’s and Neonet’s clients to access a more complete range of international execution services and capabilities.

The acquisition was granted the relevant approvals from the Swedish Financial Supervisory Authority on 6 September and was completed on 14 September 2016.

Vinge’s team consisted of among others partners Daniel Rosvall (M&A) and Emma Stuart-Beck (Financial Services) as well as associates Samra Baytar (M&A), Caroline Krassén and Henrik Schön (Financial Services).


 

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025